The immunological response to spinal cord injury: Helpful or harmful?

Experimental Neurology

Volumn 247, Issue , 2013, Pages 282-285

  Laliberte, A M ^a,b   Fehlings, M G ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FINGOLIMOD; GLIAL FIBRILLARY ACIDIC PROTEIN; RAG2 PROTEIN;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; B LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUROIMMUNOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINATION ACTIVATING GENE 2 GENE; SPINAL CORD INJURY; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; FEMALE; NERVE REGENERATION; RECOVERY OF FUNCTION; SPINAL CORD INJURIES; T-LYMPHOCYTES;

EID: 84881367329     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.01.008     Document Type: Note

References (41)

1. Ankeny D.P., Popovich P.G. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 2009, 158:1112-1121.
2. Ankeny D.P., Popovich P.G. B cells and autoantibodies: complex roles in CNS injury. Trends Immunol. 2010, 31:332-338.
3. Ankeny D.P., Lucin K.M., Sanders V.M., McGaughy V.M., Popovich P.G. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J. Neurochem. 2006, 99:1073-1087.
4. Ankeny D.P., Guan Z., Popovich P.G. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J. Clin. Invest. 2009, 119:2990-2999.
5. Arnold S.A., Hagg T. Anti-inflammatory treatments during the chronic phase of spinal cord injury improve locomotor function in adult mice. J. Neurotrauma 2011, 28:1995-2002.
6. Aubin E., Lemieux R., Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010, 115:1727-1734.
7. Bieber A.J., Kerr S., Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann. Neurol. 2003, 53:680-684.
8. Chaitanya G.V., Kolli M., Babu P.P. Granzyme-b mediated cell death in the spinal cord-injured rat model. Neuropathology 2009, 29:270-279.
9. Chen M.S., Huber A.B., van der Haar M.E., Frank M., Schnell L., Spillmann A.A., Christ F., Schwab M.E. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 403:434-439.
10. Devivo M.J. Epidemiology of spinal cord injury. Spinal Cord Medicine Principles and Practice 2010, 78-84. Demos Medical Publishing, New York, NY. V.W. Lin (Ed.).
11. Dorner T., Radbruch A., Burmester G.R. B-cell-directed therapies for autoimmune disease. Nat. Rev. Rheumatol. 2009, 5:433-441.
12. Gonzalez R., Hickey M.J., Espinosa J.M., Nistor G., Lane T.E., Keirstead H.S. Therapeutic neutralization of CXCL10 decreases secondary degeneration and functional deficit after spinal cord injury in mice. Regen. Med. 2007, 2:771-783.
13. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E., Mor F., Leibowitz-Amit R., Pevsner E., Akselrod S., Neeman M., Cohen I.R., Schwartz M. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J. Neurosci. 2000, 20:6421-6430.
14. Hauben E., Agranov E., Gothilf A., Nevo U., Cohen A., Smirnov I., Steinman L., Schwartz M. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 2001, 108:591-599.
15. Hauben E., Ibarra A., Mizrahi T., Barouch R., Agranov E., Schwartz M. Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:15173-15178.
16. Held K.S., Steward O., Blanc C., Lane T.E. Impaired immune responses following spinal cord injury lead to reduced ability to control viral infection. Exp. Neurol. 2010, 226:242-253.
17. Ibarra A., Jimenez A., Cortes C., Correa D. Influence of the intensity, level and phase of spinal cord injury on the proliferation of T cells and T-cell-dependent antibody reactions in rats. Spinal Cord 2007, 45:380-386.
18. Jones T.B., Basso D.M., Sodhi A., Pan J.Z., Hart R.P., MacCallum R.C., Lee S., Whitacre C.C., Popovich P.G. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 2002, 22:2690-2700.
19. Jones T.B., Ankeny D.P., Guan Z., McGaughy V., Fisher L.C., Basso D.M., Popovich P.G. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J. Neurosci. 2004, 24:3752-3761.
20. Kipnis J., Mizrahi T., Hauben E., Shaked I., Shevach E., Schwartz M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15620-15625.
21. Lee K.D., Chow W.N., Sato-Bigbee C., Graf M.R., Graham R.S., Colello R.J., Young H.F., Mathern B.E. FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. J. Neurotrauma 2009, 26:2335-2344.
22. Lonjon N., Boniface G., Feifel R., Endres R., Gimenez y Ribotta M., Privat A., Perrin F.E. Potential adverse effects of cyclosporin A on kidneys after spinal cord injury. Spinal Cord 2011, 49:472-479.
23. Lu H.Z., Xu L., Zou J., Wang Y.X., Ma Z.W., Xu X.M., Lu P.H. Effects of autoimmunity on recovery of function in adult rats following spinal cord injury. Brain Behav. Immun. 2008, 22:1217-1230.
24. Lu H.Z., Wang Y.X., Zhou J.S., Wang F.C., Hu J.G. Cyclosporin A increases recovery after spinal cord injury but does not improve myelination by oligodendrocyte progenitor cell transplantation. BMC Neurosci. 2010, 11:127.
25. Lucin K.M., Sanders V.M., Popovich P.G. Stress hormones collaborate to induce lymphocyte apoptosis after high level spinal cord injury. J. Neurochem. 2009, 110:1409-1421.
26. Martinon S., Garcia E., Gutierrez-Ospina G., Mestre H., Ibarra A. Development of protective autoimmunity by immunization with a neural-derived peptide is ineffective in severe spinal cord injury. PLoS One 2012, 7:e32027.
27. Mbye L.H., Singh I.N., Carrico K.M., Saatman K.E., Hall E.D. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J. Cereb. Blood Flow Metab. 2009, 29:87-97.
28. McMahon S.S., Albermann S., Rooney G.E., Moran C., Hynes J., Garcia Y., Dockery P., O'Brien T., Windebank A.J., Barry F.P. Effect of cyclosporin A on functional recovery in the spinal cord following contusion injury. J. Anat. 2009, 215:267-279.
29. Nguyen D.H., Cho N., Satkunendrarajah K., Austin J.W., Wang J., Fehlings M.G. Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury. J. Neuroinflammation 2012, 9:224.
30. Potas J.R., Zheng Y., Moussa C., Venn M., Gorrie C.A., Deng C., Waite P.M. Augmented locomotor recovery after spinal cord injury in the athymic nude rat. J. Neurotrauma 2006, 23:660-673.
31. Riegger T., Conrad S., Liu K., Schluesener H.J., Adibzahdeh M., Schwab J.M. Spinal cord injury-induced immune depression syndrome (SCI-IDS). Eur. J. Neurosci. 2007, 25:1743-1747.
32. Riegger T., Conrad S., Schluesener H.J., Kaps H.P., Badke A., Baron C., Gerstein J., Dietz K., Abdizahdeh M., Schwab J.M. Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience 2009, 158:1194-1199.
33. Saganova K., Orendacova J., Sulla I., Filipcik P., Cizkova D., Vanicky I. Effects of long-term FK506 administration on functional and histopathological outcome after spinal cord injury in adult rat. Cell. Mol. Neurobiol. 2009, 29:1045-1051.
34. Saxena K., Patro N., Patro I. FK506 protects neurons following peripheral nerve injury via immunosuppression. Cell. Mol. Neurobiol. 2007, 27:1049-1057.
35. Shihabuddin L.S., Ray J., Gage F.H. FGF-2 is sufficient to isolate progenitors found in the adult mammalian spinal cord. Exp. Neurol. 1997, 148:577-586.
36. Stangel M., Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J. Neurol. 2006, 253(Suppl. 5):V18-V24.
37. Trepanier P., Bazin R. Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation. Blood 2012, 120:2769-2770.
38. Wu B., Matic D., Djogo N., Szpotowicz E., Schachner M., Jakovcevski I. Improved regeneration after spinal cord injury in mice lacking functional T- and B-lymphocytes. Exp. Neurol. 2012, 237:274-285.
39. Yoles E., Hauben E., Palgi O., Agranov E., Gothilf A., Cohen A., Kuchroo V., Cohen I.R., Weiner H., Schwartz M. Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 2001, 21:3740-3748.
40. Yu W.R., Fehlings M.G. Fas/FasL-mediated apoptosis and inflammation are key features of acute human spinal cord injury: implications for translational, clinical application. Acta Neuropathol. 2011, 122:747-761.
41. Ziv Y., Avidan H., Pluchino S., Martino G., Schwartz M. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13174-13179.